LAVA Therapeutics (LVTX.US): The 2024 Q1 financial report achieved revenue of US$6.992 million, with a previous value of US$1,224 million and an expected value of US$7 million; earnings per share were -0.02 USD, previous value of -0.53 USD, and expected value of -0.12 USD.
LAVA Therapeutics(LVTX.US)：2024年Q1财报实现营收699.2万美元，前值为122.4万美元，预期值为700万美元；每股收益为-0.02美元，前值为-0.53美元，预期值为-0.12美元。
LAVA Therapeutics (LVTX.US): The 2024 Q1 financial report achieved revenue of US$6.992 million, with a previous value of US$1,224 million and an expected value of US$7 million; earnings per share were -0.02 USD, previous value of -0.53 USD, and expected v
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.